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schizophrenia in outpatient treatment
settings: a randomized controlled single-
blind trial
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Abstract
Background: Shared decision making (SDM) is often defined as an interactive process that ensures that both patient
and practitioner are actively involved in the treatment and that they share all relevant information to arrive at a mental
health decision. Previous SDM interventions have found improvements in outcomes such as personal recovery, higher
perceived involvement in treatment decisions and knowledge about one’s disease. Still, SDM occurs less frequently in
mental health care than in primary care. Electronic aids developed to support patient activation and SDM could be a
promising mean to engage patients in their mental healthcare.
The aim of this trial is to investigate the effects of using a smartphone app to promote patient activation and support
SDM for people with schizophrenia-spectrum disorders in an outpatient treatment setting.
Methods: This randomised controlled trial will allocate participants to one of two groups: (1) Intervention
group: smartphone app and TAU (treatment as usual) or (2) Control group: TAU without the smartphone app.
A total sample size of 260 people with a diagnosis of schizophrenia, schizotypal or delusional disorder will be recruited
from five OPUS teams (a specialized early intervention program) in Denmark between 2019 and 2020. The intervention
will last for 6 months with data collection at baseline, and at 3 and 6months. Primary outcome will be self-perceived
patient activation. Secondary outcomes will be feeling of being prepared for SDM; self-efficacy; working alliance;
treatment satisfaction; positive and negative symptoms; level of functioning; hope; and perceived efficacy in
patient-provider interaction. Patients’ and health providers’ preferences in clinical decision making will be assessed.
Patients’ usage and perceived usefulness of the app will be explored.
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Discussion: This study will investigate the efficacy of using the smartphone app to support people with severe mental
illness in engaging in their own healthcare management. The study may provide evidence to the idea that linking
client and practitioner in digital solutions can have advantages in facilitating SDM in mental health. The trial will
provide new knowledge of whether a digital healthcare solution can improve patient activation and support SDM for
people with severe mental illness.
Trial registration: ClinicalTrials.gov number: NCT03554655 Registered on: June 13, 2018.
Keywords: Shared decision making, Patient activation, Schizophrenia, Schizotypal, Early intervention, First-episode
psychosis, mHealth, Randomized clinical trial
Background
Shared decision making (SDM) is often defined as an
interactive process that ensures that both patient and
practitioner are actively involved in the treatment and
that they share all relevant information in order to arrive
at a mental health decision [1, 2]. While practitioners
provide a professional expertise with information on the
diagnosis, course of the illness, treatment options and
potential side effects, patients are experts on their own
needs, treatment preferences and goals [1]. Working
together with their unique competences, SDM can be con-
ceptualized as an intermediate position on a continuum
with clinician-led decisions at one end and patient-led
decisions at the other end [3].
In mental healthcare, SDM has been assessed as a
promising treatment intervention with research studies
indicating that SDM interventions may promote personal
recovery [4], lead to more positive attitude towards medi-
cation [5], improve adherence with treatment [5], improve
knowledge about the disease [6], lead to a higher per-
ceived involvement in treatment decisions [6, 7], promote
patient activation in treatment consultations [8] and may
increase satisfaction with treatment decisions [7]. On a
more ethical note, becoming more active and engaged in
one’s own healthcare is an important element for the
patient to (re)gain control and responsibility over his/her
own life and recovery process [9]. In addition, clinical
guidelines advocate the use of SDM as a patient-centered
mental healthcare [10, 11].
Although the current evidence on the efficacy of SDM in-
terventions in mental healthcare appears to be encouraging,
the evidence is limited mainly due to a lack of high quality
RCT studies and implementation challenges [3, 12]. A
central challenge for studies investigating SDM is the
complexity of SDM since addressing all of its components
into one trial might not be feasible. SDM is a highly com-
plex intervention including a wide range of characteristics
(defining the problem, outlining options, reaching a
mutual agreement etc.) while also being dependent on
a number of mechanics surrounding the patient and
provider (e.g. alliance, communication, preferences and
engagement) [13]. Research studies often tend to only
focus on certain components of SDM (e.g. SDM training
for providers or a decision aid for patients) [13], which
could help explain why many RCTs are not finding diffe-
rences between intervention and control subjects.
Although clinical guidelines encourage mental healthcare
providers to engage patients in treatment decisions, only
few healthcare providers consistently attempt to engage
patients in their treatment or adjust the care to the patient’s
preferences [14]. This may contribute to the discrepancy
between SDM being a preferred model for clinical
decision-making for many patients and providers in mental
healthcare [15, 16] and patients indicating that they are not
involved as much as they want to be in their treatment
[17]. The feeling of being involved or as an active partici-
pant in one’s mental healthcare may improve affective-cog-
nitive outcomes (e.g. alliance with provider or
satisfaction with care), behavioural outcomes (e.g. engage-
ment in treatment such as decision making) and health
outcomes (e.g. symptom reduction) [18]. In addition,
active or engaged patients with higher expectations for
collaborative care could also activate their provider in
more collaborative care, thereby creating a good foun-
dation for SDM [19].
One potential mean to facilitate SDM in mental healthcare
could be the use of mHealth (mobile healthcare), thereby
linking patients and providers together in computer-medi-
ated interventions [20, 21]. A majority of younger psychiatric
patients (< 45 years old) indicates an interest in using smart-
phone apps to evaluate their mental health [22] and a
Cochrane review on decision aids (not only mHealth) found
improvements in participant’s level of knowledge, patient-
clinician communication, participation in treatment
and satisfaction with the decision-making process [23].
Few studies have investigated the use of digital solutions
in facilitating SDM in mental health and the evidence on
the beneficial and possible harmful effects of using such
tools in people with severe mental illness are scarce and
limited by a lack of randomized controlled trials (RCT).
These RCTs do, however, suggest that electronic aids to
support SDM are a promising mean to engage patients in
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their mental health treatment [20, 24–26]. Multiple sys-
tematic reviews highlight a need for more evidence-based
research on the efficacy and effectiveness of mental
health apps [27–30].
This protocol describes a RCT to investigate the effects
of using a smartphone app to promote patient activation
and support SDM in mental healthcare. Engaged or active
patients have been defined as patients being able to; take an
active role in the treatment; collaborate with their mental
healthcare provider (e.g. communicate concerns, needs and
preferences, discuss treatment options and make treatment
decisions) and; manage their symptoms and condition [31].
The system being used in the trial consists of a smart-
phone app (for the patient) and a web portal (for the
provider). Information entered in the app by the patient
will automatically be transferred to the web portal for
the provider to see. This procedure will give the patient
and the provider an option for a common starting point
when meeting for consultations. Since decisions in men-
tal healthcare often are an ongoing process, the smart-
phone app is not a classic decision aid focusing on
finding a choice to a one-off decision at a single point in
time. Instead, the smartphone app presented in this trial
is an aid to support some of the underlying elements be-
hind SDM such as engagement in care, collaboration
with one’s provider, awareness and eliciting of one’s
needs, preferences and values. The app consists of the
following functions:
 Questions with multiple choices to prepare
for treatment consultation (e.g. what have
been important to you since your last visit?)
 Daily self-evaluation on parameters such as
stress, sleep and well-being
 Plans for action (e.g. recovery goal setting,
personal strategies, crisis plan)
 Forms for evaluating treatment consultations
(e.g. did you and your treatment provider
discuss what you needed?).
The app was developed in the period of 2013–2014 in
the Mental Health Services of the Capital Region of
Denmark in a process of co-creation between re-
searchers, mental health providers and people with
schizophrenia-spectrum disorders. Afterwards, the app
was tested in a pilot study including 116 mental health
professionals and 78 patients from three different mental
health treatment sites: community of mental health, in-
patient- and outpatient treatment sites. Based on the
pilot study, the app was assessed most relevant in out-
patient treatment sites [32]. The app has since in a de-
velopment process with the Monsenso mHealth solution
for mental health been optimized by incorporating the
functionalities of preparing and evaluating treatment
consultations from the app used in the pilot study, while
adding options for daily self-evaluation and goal setting.
This optimization was done based on the feedback re-
ceived from the study participants in the pilot study.
The app is in the trial driven by Monsenso ApS.
Methods/Design
The aim and purpose of this trial is to investigate the
effects of using the smartphone app for people with a
diagnosis of schizophrenia, schizotypal or delusional disor-
ders within outpatient treatment settings in a randomized
design on selected outcomes. Our main hypothesis is that
patients using the smartphone app in combination with
receiving specialized early intervention treatment (which
in this study is treatment as usual (TAU)), compared to
patients only receiving TAU, will show greater improve-
ments in patient activation, measured by the Consumer
Health Activation Index – Mental Health version
(CHAI-MH), 6months after baseline (primary outcome).
Our secondary hypothesis is that patients using the smart-
phone app in combination with receiving TAU, compared
to patients only receiving TAU, will show greater improve-
ments regarding self-perceived patient preparedness for
SDM; self-efficacy; the therapeutic alliance; severity of
symptoms; level of functioning; hope and optimism; satis-
faction with treatment and; patient’s confidence in com-
municating preferences and concerns to their provider
(secondary outcomes). Lastly, we will investigate whether
there is a correlation between the effects of using the
smartphone app and self-reported usefulness of the
smartphone app and/or app usage (user sessions per day,
screen views per day, screens per session, session duration
and user retention) (explorative outcomes).
The Momentum trial is designed as a multi-centre,
two-arm, parallel-group, observer-blinded block ran-
domised controlled trial. Based on a power calculation a
total of 260 participants, 130 in each arm will be recruited
from five outpatient treatment sites called OPUS in the
Capital Region of Denmark. Five sites were chosen based
on their current number of patients and their yearly
uptake of new patients. OPUS teams provide specialized
early intervention (SEI) treatment to patients with a
debuting diagnosis of schizophrenia or related psychotic
disorders in the age group of 18–35 in Denmark. For this
study, SEI treatment in OPUS will be considered as treat-
ment as usual (TAU). The trial will compare two groups
receiving TAU with one of the groups also using a
smartphone-based aid to promote patient activation and
support SDM (see Fig. 1).
Description of study participants
Patients will be referred to the research team through their
OPUS contact person. Patients will be eligible for the study
if the patient meets the inclusion and exclusion criteria.
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The inclusion criteria of the study are:
 Adults of both sexes aged 18+
 A diagnosis of schizophrenia, schizotypal or
delusional disorder (ICD-10 codes: F20–F29)
 The patient has received treatment for a maximum
of 18 months at the start of the intervention from
one of five participating OPUS centres in the
Mental Health Services of the Capital Region of
Denmark
The exclusion criteria of the study are:
 Do not understand or speak Danish
 Unable to give written informed consent to
participate in the trial at the described terms
 Are participating in other research studies
involving OPUS treatment and an app
 Do not have daily access to a smartphone
 Are suffering of cognitive impairment
or dementia (F. 70-F.79, F.00-F.03)
Criteria for discontinuing the intervention:
 If the patient stops his/her OPUS treatment or
withdraws informed consent, they will be
excluded from the intervention. Patients not
receiving the full intervention will still be
assessed at follow-up.
Enrolment
The first contact with potential participants is done
through the patient’s primary contact person in OPUS
who has been informed about the Momentum trial. The
patient will be provided with a written information sheet
about the Momentum study by the contact person. The
primary contact person will evaluate in collaboration with
the patient whether the patient is fit to participate in the
study or not. If the patient is interested, the patient will be
invited to an information meeting with a researcher.
Patients will be informed that they are welcome to bring
relatives or friends to the meeting. The researcher will
assess whether the patient meets the inclusion criteria and
deliver verbal and written information about the study in
Fig. 1 Flow-chart for The Momentum Trial
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an undisturbed office. Patients who wish to participate will
be required to give verbal and written informed consent. 2
weeks of reflection time prior to consent will be offered.
The baseline assessments will be conducted when the
informed consent has been obtained, (see Table 1).
Randomization and blinding
Randomisation to either the intervention group (TAU +
smartphone app) or control group (only TAU) will be
performed after baseline assessments. To achieve balance
in the allocation of participants to treatment arms and to
reduce risk of bias, block randomization of randomly
determined block size will be used. To ensure adequate al-
location concealment, the procedure will be centralised
and computerised with concealed randomisation sequence
facilitated by Odense Patient data Explorative Network
(OPEN). Investigators will contact the randomisation unit,
OPEN, with the necessary information to conduct the
randomisation after baseline data have been collected.
Given the nature of the intervention, patients and
healthcare providers cannot be kept blinded. Investi-
gators responsible for data collection and data entry will
be blinded as to patient allocation until all outcomes
have been collected. Participants are given an identifi-
cation number to ensure that the research team involved
in data management are unaware of the treatment allo-
cation. All patients are at each visit with the researcher
thoroughly instructed not to mention anything about
randomization allocation.
Intervention
Patients allocated to the intervention group will receive
TAU together with a manual-based introduction to the
smartphone app with instructions on how to install and
use the app. Once the app is installed, participants will
Table 1 SPIRIT schedule of enrolment, interventions, and assessment
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be able to use the app until the end of the study. All
participants are encouraged to use the app for 5min per
day to perform self-evaluation on parameters such as
stress and sleep. Similarly, providers will be encouraged to
use the web portal to check what input the patient has
made in the app before a consultation (approximately
once per week per patient). Both the control- and inter-
vention group will receive TAU, which is provided by
OPUS, a specialized assertive outpatient intervention for
people age 18–35 years with a first episode psychosis.
OPUS provides an integrated treatment approach by
multidisciplinary staff (psychiatrists, psychologists, nurses,
social workers etc.), including psychosocial interventions
(e.g. psychoeducation and social skills training), for a
period of 2 years. The treatment programme has been
found to be effective at reducing negative- and psychotic
symptoms [33]. Patients starting in OPUS are designated a
healthcare provider, who has the responsibility as the
patient’s primary contact person. All staff in OPUS may
act as a primary contact person (except for the psy-
chiatrist) and receives continually training and supervision
in providing SEI treatment to people with a first episode
psychosis. In collaboration with the patient, the treatment
team assesses the most promising strategy to accommo-
date the patient’s needs and preferences. On average,
primary contact persons in OPUS have 12–15 patients.
Assessments
Communication between patient and provider (including
SDM) may lead directly to improved health outcomes
but more often communication affects health outcomes
indirectly [18]. For instance, a SDM intervention could
improve treatment satisfaction resolving in a promotion
of health behaviour which lastly may end up improving
different important health outcomes (e.g. reduction of
symptoms). The conceptual framework by Shay and
Lafata describes the link between SDM and affective-
cognitive outcomes (e.g. alliance and satisfaction), be-
havioural outcomes (e.g. activation or engagement) and
health outcomes (e.g. symptom reduction) [18]. Therefore,
these areas will be measured during the intervention.
Patient activation (behavioural outcome) was chosen as
our primary outcome because of our intervention being
primarily patient-centred. Prior to the data collection, we
conducted a pilot study in OPUS with 8% of our proposed
sample size (21 patients) to test the primary outcome
(CHAI-MH). Furthermore, all questionnaires were tested
with patients from OPUS to ensure that questions were
understandable and unambiguous. The pilot test showed
no ceiling effects or issues regarding the understanding of
the questionnaires.
Participants will be assessed at three-time points: at
baseline, after 3months and after 6months (end of inter-
vention). Clinicians will be assessed at baseline and when
each of their participating patients completes the 6
months intervention period. In case of non-respondents,
participants will be contacted after 2 weeks with a
reminder to complete the survey.
Baseline parameters
For all patients enrolled, information on patient charac-
teristics, diagnosis and duration in OPUS treatment will
be collected. Data on diagnosis are used as an inclusion
criterion while data on duration in OPUS treatment will
be used to assess whether the smartphone app has a
different effect based on the duration of receiving OPUS
treatment. Background characteristics for the clinicians
will also be collected. Since preferences in clinical deci-
sion making have been found to be related to patient
involvement [34], the Clinical Decision Making Style
questionnaire (CDMS) will be collected at baseline. The
CDMS is a self-reported 21-item measure for the assess-
ment of preferences in clinical decision making [16].
The scale consists of two subscales: 1) Participation in
Decision Making (PD) and 2) Information (IN). The
questionnaire is rated on a 5-point Likert scale and has
been developed in two versions – one for patients and
one for provider. The PD subscale has good internal
consistency (Cronbach’s α = .85–.89), while the IN sub-
scale has an acceptable internal consistency (Cronbach’s
α = .75–.81). The PD and IN subscales do not correlate
indicating convergent validity (i.e. preferences for
participation in decision making are independent of
preferences for information) [16]. In the present study,
patients and their primary provider will be asked to
complete the questionnaire to determine their level of
agreement. The scale will only be used at baseline due to
research indicating that the CDMS scoring is moderately
to highly stable over 12 months [16].
Primary outcome
The primary outcome of this trial is the difference in
patient activation before participating in the trial and
after 6 months participation. This will be assessed using
the Consumer Health Activation Index for mental health
(CHAI-MH) [35]. The 10-item instrument was deve-
loped based on 5 key domains: knowledge, self-efficacy,
motivation and beliefs, actions, and internal locus of
control. The questionnaire is rated on a 6-point Likert
scale ranging from “Strongly disagree” to “Strongly
agree”. Afterwards, the scores are transformed into a
theoretical value from 0 to 100, with higher scores signi-
fying a stronger involvement in the treatment and confi-
dence in the ability to take care of one’s own health and
health treatment. Higher CHAI scores have been asso-
ciated with fewer depressive and anxiety symptoms.
CHAI has been found valid and reliable while having
good internal consistency (Cronbach’s α = .91) [35]. For
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this study the CHAI was modified to mental health.
Hence, the mental health version of CHAI (CHAI-MH)
has not yet been validated. The CHAI-MH was trans-
lated to Danish using a thorough forward/backwards
translation process with three independent translators.
Secondary outcomes
Based on the conceptual framework of Shay and Lafata
[18], the study will investigate whether the smartphone
app will improve the patient’s preparedness for SDM,
self-efficacy, patient’s alliance with the clinician, severity
of symptoms, level of functioning, hope, and treatment
satisfaction. These outcomes will be obtained at baseline
and after 6 months. In addition, the feeling of hope,
self-efficacy and communication with one’s clinician will
be obtained after 3 months.
The Preparation for Decision Making (PrepDM) scale is
a self-reported 10-item instrument to measure the
patient’s perception of how useful a decision aid or other
decision support intervention is in preparing the respon-
dent to communicate with their practitioner at a con-
sultation focused on making health decisions [36]. The
questionnaire is rated on a 5-point Likert scale from “Not
at all” (1) to “A great deal” (5) with higher scores indi-
cating a higher level of preparedness to communicate with
one’s care provider regarding health decisions. The
PrepDM has been validated with high internal consistency
(Cronbach’s α = .92 to .96) [36]. The PrepDM scale will be
translated to Danish for this study using the forward/back-
wards translation process. The General Self-Efficacy Scale
(GSE) measures the patient’s belief that one’s actions are
responsible for successful outcomes [37]. The questions
consist of 10 items rated on a 4-point Likert scale ranging
from “not at all true” (1) to “exactly true” (4) with higher
scores indicating higher self-efficacy. The scale has
been validated and found reliable in psychiatric care
with the Danish version having good internal consistency
(Cronbach’s α = .87) [38].
The Working Alliance Inventory-short (WAI) measures
the therapeutic alliance between patients and clinicians
within three domains; goals; tasks; and bond [39]. The
questionnaire consists of 12 items rated on a 7-point
Likert scale, with higher scores indicating better
working alliance. The scale has been developed in two
versions – one for patients and one for provider – and will
in this study be filled out by patients and by the primary
providers. Providers will fill out the instrument for each of
their own patients participating in the study. The scale
has good internal consistency (Cronbach’s α = .83–.98)
and high correlation with the original WAI [40].
Perceived hope and optimism will be measured using
the Adult State Hope Scale (ASH). The 6-item instru-
ment is rated on a Likert-scale from 1 to 8, with higher
scores indicating higher levels of hope [41]. The scale
has been validated and shows good internal consistency
(Cronbach’s α = .93). Psychometrically testing in various
settings has shown the scale to be appropriate for
self-report on hope and optimism in people with severe
mental illnesses [42].
The Perceived Efficacy in Patient-Physician Interactions
Questionnaire (PEPPI) is a self-reported 5-item instrument
for the assessment of patient’s confidence in communi-
cating with their physician [43]. The questionnaire is rated
on a 10-point Likert scale, with higher scores indicating
higher perceived efficacy in the interactions. The scale has
been found to be valid and reliable in somatic care with
excellent internal consistency (Cronbach’s α = .92) [43].
The scale will be translated to Danish for this study using
the forward/backwards translation process.
The Client Satisfaction Questionnaire (CSQ) is a self-re-
ported 8-item measure to assess a patient’s satisfaction
with treatment. Each item is scored on a 4-point Likert
scale, with higher scores indicating higher satisfaction.
The CSQ has shown good psychometric properties with a
high internal consistency (Cronbach’s α = .93) [44].
The Service Engagement Scale (SES) is a 14-item
measurement for the provider to rate their patient’s
engagement level on four subscales ‘availability’, ‘colla-
boration’, ‘help seeking’ and ‘treatment adherence’ [45].
Each item is scored on a 4-point Likert scale, with higher
scores indicating poorer engagement. For this study, only
the subscale ‘collaboration’ will be used, consisting of 3
questions. The SES has shown good psychometric proper-
ties and has previously been used in studies with patients
with psychotic disorders [45].
To assess positive and negative symptoms, the Scale
for the Assessment of Positive Symptoms (SAPS) and
Scale for the Assessment of Negative Symptoms (SANS)
will be used. The two scales consist of 3 dimensions: the
psychotic, the disorganized, and the negative. Each
dimension is scored between 0 and 5 with higher scores
indicating higher symptom severity. Social functioning will
be assessed using the Global Assessment of Function
(GAF) and Personal and Social Performance Scale (PSP).
GAF assesses a person’s psychosocial functioning (scores
1–100), with higher scores indicating a higher functioning
level. GAF has been found highly generalizable and has
been validated as a useful means of assessing global
psychosocial health in people with psychotic symptoms
[46, 47]. PSP assesses a person’s functioning level within
four domains; socially useful activities; Personal and social
relationships; Self-care; Disturbing and aggressive be-
haviors. PSP is scored 1–100, with higher scores indicating
a higher functioning level. PSP has been found reliable
and valid as a measure of social functioning in patients
with schizophrenia [48].
Another aspect of interest is on whether the use of the
smartphone app may affect adherence to treatment
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appointments, medication and/or hospital admissions.
To measure this, data on patient adherence to OPUS
appointments and number of hospitalizations will be
collected from the patient journals while information on
the usage of anti-psychotic medication will be collected
through the patient interviews.
Explorative outcomes
To explore the intervention group’s satisfaction of the
app, the App Rating Questionnaire (ARQ) will be used
in combination with objective data on app usage (user
sessions per day, screen views per day, screens per session,
session duration and session instances, user retention).
The ARQ seeks to capture the end users perceptions of a
software application [49]. The scale consists of 4 items
scored on a 4-point Likert scale ranging from “Strongly
agree” to “Disagree”.
Data management
All the above-mentioned outcomes except for SAPS, GAF
and PSP are either patient- or provider-reported outcome
measures and will be collected through self-administered
web-based questionnaires. Patients will complete the
questionnaires on an iPad provided by the researcher.
Questionnaires in paper format will be offered as an alter-
native. The completion of the questionnaires will be done
in the presence of a researcher to clarify any uncertainties
participants may have regarding the questionnaires. Ques-
tionnaires will be collected and managed using REDCap
electronic data capture tools hosted at the The Mental
Health Services of the Capital Region [50]. REDCap
(Research Electronic Data Capture) is a secure, web-based
application designed to support data capture for research
studies. REDCap has a complete log and audit trail and
complies with Danish legislation on processing personal
data. Access to study data will only be available for data
managers. Participants will receive an e-mail with a link to
the questionnaires. Participants will have to login to a
secure portal using a unique password, which is deliv-
ered at the patient’s meetings with the researcher.
Interview-based data (such as SAPS, SANS, GAF and
PSP) will be written directly into REDCap by the re-
searcher. Information on diagnosis, hospital admissions,
duration in OPUS treatment and adherence to treatment
appointments will be collected retrospectively and
retrieved from the patient journals.
Power and sample size
The power calculation is based on the results of 6 RCT
studies investigating patient activation using the Patient
Activation Measure as a primary outcome [51–56], and
by using the PS Power and Sample Size Calculations
program version 3.1.2. This was done due to a lack of
RCTs using the CHAI scale. While these studies use a
different scale, they do measure the same domain:
patient activation. We calculated our planned sample
size based on the effect size on patient activation for
these 6 studies. These studies had a mean effect size of
0,42, ranging from 0,28 – 0,65. Based on these studies,
we expect to find an effect size between our intervention
and control group of 0,42. To reach a power 80% and
alpha of 0,05 we will need 90 participants in each group
to be able to reject the null hypothesis that the popu-
lation means of the two groups are equal. We plan on
having 1 control per intervention subject. With an ex-
pectation of approximately 30% dropouts, we will
include 130 participants in each group for a total of 260
participants. In addition, we performed sample size
calculations for several secondary outcomes. None of
these calculations exceeded 260 participants to detect a
significant statistical difference for some of our second-
ary outcomes as well as our primary outcome.
Statistical analysis
The analysis will be performed by using the IBM
SPSS and SAS. Significance levels below 0,05 will be
considered significant for the analysis of primary and
secondary outcomes.
The data analysis will be conducted accordingly to
the principle of intention-to-treat (i.e. patients will be
included in the analysis according to group assignment
even if they do not receive all of the planned intervention).
In case of missing data, the operation of multiple impu-
tations will be used to address the issue of missing values.
To validate the complete case analyses, an analysis of the
drop outs will be conducted.
With multiple assessment points, we will use mixed-ef-
fects linear regression for the primary analysis. The
mixed-effects model is chosen to account for the depend-
ency inherent in the data due to repeated measurements
and to allow respondents with missing observations at
different time points. If relevant, subsequent statistical
tests will be performed. Cohens Kappa will be performed
to determine the level of agreement between the patients
and providers..
If any of our outcomes do not meet the assumptions
for parametric statistical tests, data will either be trans-
formed as appropriate prior to analysis or replaced by
non-parametric statistical tests.
Discussion
The Momentum trial is to our best knowledge the first
randomized controlled trial to evaluate the effectiveness
of a smartphone application to engage people with
schizophrenia-spectrum disorders in their treatment
consultations to support patient activation and SDM. The
intervention will focus on supporting patients through the
smartphone app to become more active in their care
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(primary outcome). In addition, the intervention will also
connect patients together with their providers (through a
web portal) to gain a common starting point before treat-
ment consultations. We expect that the combination of
patients becoming more active in their care together with
having their data shared with the provider will improve
the patient’s preparedness for SDM, the therapeutic
alliance, the efficacy of therapeutic interactions, hope,
self-efficacy, severity of symptoms and level of functioning
(secondary outcomes).
A major strength of the study is the comprehensive
pilot study prior to the trial. While the trial is primarily
focusing on quantitative assessments, the pilot study was
mainly qualitative with a focus on identifying needs and
preferences in the target group in relation to a smart-
phone app to support SDM. Another strength of the
study is the focus and assessment on both patient and
provider. Research indicates that addressing data from
patients and providers together may yield more powerful
effects than only focusing on one of the two [8]. Infor-
mation from both perspectives will also provide valuable
information on how patients and providers view their
alliance. In addition, providers will be asked to rate the
patient’s engagement level to compare this with the
patient’s own perceived level of engagement. Finally, we
have a solid sample size calculation to perform a data
analysis with good strength regarding our primary out-
come and several secondary outcomes.
The methodical limitations in this study may be that
since providers are not blinded and potentially are going
to have participating patients from the control- and the
intervention group, a contamination bias could occur.
Providers may gain experience in the concepts of SDM
from working with patients in the intervention group
which they then could apply (intentionally or uninten-
tionally) to their patients in the control group. The study
is also at risk of a recruitment bias if providers mainly
recruit patients who are rather stable and therefore not
completely representable of OPUS patients. To address
this, we will throughout the recruitment period encourage
providers to inform all of their patients about the study
regardless of the patient’s level of functioning. Based on
prior studies using mobile applications, we estimate a
drop out level of 30%. To address the risk of patients not
using the app consistently, the user will have the option
within the app to setup daily reminders to use the app.
A drop out analysis will be conducted to identify poten-
tial characteristics of those dropping out or who stop
using the app.
A limitation for this study is the lack of qualitative
data. Qualitative interviews performed after the inter-
vention to explore the participants’ experiences of the
smartphone app in relation to SDM is being considered.
Observational measures on the interactions between
patient and provider to observe potential changes in the
decision-making process and on how the app is used in
the consultations would be meaningful. If feasible, inter-
views and observational measures will be performed
after the end of the intervention. Although patients and
providers are encouraged to include the smartphone app
in the consultations when relevant, it is unknown to
what extent this will happen. To address this, patients in
the intervention group will be asked at the end of the
intervention approximately how often they included the
app in the consultation and whether it was the patient
or the provider who took the initiative to include the
app. Although OPUS is a well-established treatment site,
OPUS was chosen as our study site due to providing a
high feasibility for conducting research studies and due
to our pilot study indicating that younger adults with
schizophrenia-spectrum disorders indicate that an easy
accessible solution, such as the smartphone app pre-
sented in this trial is a relevant tool to better prepare for
treatment consultations and to take a more active role in
the treatment [32]. Patients receiving OPUS treatment
meet with several staff members. Still, we chose only to
focus on the primary provider due to the fact that a pa-
tient in OPUS meets their primary provider significantly
more often than any of the other staff members (e.g. the
psychiatrist).
If the Momentum trial confirms the hypothesis that
providing people with schizophrenia-spectrum disorders
with the presented system will increase their level of ac-
tivation in the treatment and support SDM, the study
will provide evidence on the effects of using such tools
to support people with severe mental illness in engaging
in their own healthcare management. In addition, the
study may provide evidence to the idea that linking
client and practitioners in digital solutions can have
advantages in facilitating SDM in mental health. Overall,
the study will provide more evidence to the further
developing and implementation of electronic tools to
support SDM in mental health care. Future enhance-
ments will be to integrate the smartphone app with the
existing IT systems and to investigate its efficacy long
term (> 1 year) and in other mental healthcare settings.
Trial status
Inclusion of participants started in January 2019 and is
expected to end April 2020.
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